The US FDA on Friday approved Japan's Asahi Kasei's drug for persistent herpes simplex virus ​sores in certain patients with weakened immune systems ‌who have not responded to available antiviral treatments.

Log in or sign up to comment.

No comments yet.

← Back to stories